XNAS: ABUS

Download real time

3.20 -0.08 (-2.44%)

32.20% Fall from 52W High

557.9K XNAS Volume

XNAS 18 Mar, 2025 5:30 PM (EDT)

606.4

Market Cap

Below industry Median

0.1

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Arbutus Biopharma Corp is on 21 Mar 2025 for the purpose of Arbutus Biopharma Corp Annual Report for 2024 See details

Insider Trading disclosures for Arbutus Biopharma Corp

The latest disclosure was made by David C. Hastings in Arbutus Biopharma Corp where a trade of 365,800 Stock Option (Right to Buy) done was reported to US exchanges on Feb. 14, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
David C. Hastings	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Feb 2025	365,800	365,800	-		-	Stock Option (Right to Buy)
David C. Hastings	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Feb 2025	90,100	249,824 (0%)	0%		0	Common Shares
Michael J. McElhaugh	Director, Interim President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Feb 2025	177,000	1,658,003 (2%)	0%		0	Common Shares
Michael J. McElhaugh	Director, Interim President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Feb 2025	718,800	718,800	-		-	Stock Option (Right to Buy)
Karen Sims	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Feb 2025	200,300	200,300	-		-	Stock Option (Right to Buy)
Karen Sims	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Feb 2025	49,300	155,494 (0%)	0%		0	Common Shares
David C. Hastings	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 3.28 per share.	04 Feb 2025	22,183	159,724 (0%)	0%	3.3	72,827	Common Shares
Michael J. McElhaugh	Director, Interim President & CEO	Sale of securities on an exchange or to another person at price $ 3.28 per share.	04 Feb 2025	23,790	1,481,003 (2%)	0%	3.3	78,103	Common Shares
Karen Sims	Chief Medical Officer	Sale of securities on an exchange or to another person at price $ 3.28 per share.	04 Feb 2025	19,348	106,194 (0%)	0%	3.3	63,519	Common Shares
Keith Manchester	Director		14 Aug 2024	54,915	0	-		-	Stock Option (Right to Buy)
Keith Manchester	Director		14 Aug 2024	54,915	54,915 (0%)	0%	0.6	30,752	Common Shares
Keith Manchester	Director		14 Aug 2024	8,846	46,069 (0%)	0%	3.7	32,637	Common Shares
Daniel D. Burgess	Director		23 May 2024	67,000	67,000	-		-	Stock Option (Right to Buy)
James R. Meyers	Director		23 May 2024	67,000	67,000	-		-	Stock Option (Right to Buy)
Keith Manchester	Director		23 May 2024	67,000	67,000	-		-	Stock Option (Right to Buy)
Richard C. Henriques	Director		23 May 2024	67,000	67,000	-		-	Stock Option (Right to Buy)
Frank M. Torti	Director		23 May 2024	67,000	67,000	-		-	Stock Option (Right to Buy)
Melissa V. Rewolinski	Director		23 May 2024	67,000	67,000	-		-	Stock Option (Right to Buy)
Hastings C. David	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 2.31 per share.	01 Feb 2024	9,593	181,907 (0%)	0%	2.3	22,184	Common Shares
C. Hastings David	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	450,000	450,000	-		-	Stock Option (Right to Buy)
Karen Sims	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	101,000	129,900 (0%)	0%		0	Common Shares
J. McElhaugh Michael	Director, Interim President & CEO		01 Feb 2024	123,800	1,514,957 (2%)	0%		0	Common Shares
Michael J. Sofia	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	437,800	437,800	-		-	Stock Option (Right to Buy)
Karen Sims	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	403,900	403,900	-		-	Stock Option (Right to Buy)
Sofia Michael J.	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	109,500	1,495,103 (2%)	0%		0	Common Shares
Sims Karen	Chief Medical Officer	Sale of securities on an exchange or to another person at price $ 2.31 per share.	01 Feb 2024	4,358	125,542 (0%)	0%	2.3	10,078	Common Shares
J. McElhaugh Michael	Director, Interim President & CEO		01 Feb 2024	10,164	1,504,793 (2%)	0%	2.3	23,504	Common Shares
Hastings C. David	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	112,500	191,500 (0%)	0%		0	Common Shares
J. McElhaugh Michael	Director, Interim President & CEO		01 Feb 2024	495,100	495,100	-		-	Stock Option (Right to Buy)
J. Sofia Michael	Chief Scientific Officer	Sale of securities on an exchange or to another person at price $ 2.31 per share.	01 Feb 2024	9,982	1,485,121 (2%)	0%	2.3	23,083	Common Shares
Melissa V. Rewolinski	Director		12 Jul 2023	110,000	110,000	-		-	Stock Option (Right to Buy)
Karen Sims	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	10 Jul 2023	153,640	153,640	-		-	Stock Option (Right to Buy)
Daniel D. Burgess	Director		24 May 2023	55,000	55,000	-		-	Stock Option (Right to Buy)
James R. Meyers	Director		24 May 2023	55,000	55,000	-		-	Stock Option (Right to Buy)
Keith Manchester	Director		24 May 2023	55,000	55,000	-		-	Stock Option (Right to Buy)
Richard C. Henriques	Director		24 May 2023	55,000	55,000	-		-	Stock Option (Right to Buy)
Frank M. Torti	Director		24 May 2023	55,000	55,000	-		-	Stock Option (Right to Buy)
David C. Hastings	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	79,000	79,000 (0%)	0%		0	Common Shares
David C. Hastings	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	316,000	316,000	-		-	Stock Option (Right to Buy)
Michael J. Sofia	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	82,200	1,385,603 (2%)	0%		0	Common Shares
Michael J. Sofia	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	328,700	328,700	-		-	Stock Option (Right to Buy)
Elizabeth Howard	EVP, GC, Compliance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	69,700	86,024 (0%)	0%		0	Common Shares
Elizabeth Howard	EVP, GC, Compliance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	278,700	278,700	-		-	Stock Option (Right to Buy)
Michael J. McElhaugh	Chief Business Officer		01 Feb 2023	334,700	334,700	-		-	Stock Option (Right to Buy)
Michael J. McElhaugh	Chief Business Officer		01 Feb 2023	83,700	1,391,157 (2%)	0%		0	Common Shares
William H. Collier	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	866,000	866,000	-		-	Stock Option (Right to Buy)
William H. Collier	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2023	216,500	216,500 (0%)	0%		0	Common Shares
Daniel D. Burgess	Director		25 May 2022	41,000	41,000	-		-	Stock Option (Right to Buy)
James R. Meyers	Director		25 May 2022	41,000	41,000	-		-	Stock Option (Right to Buy)
Keith Manchester	Director		25 May 2022	41,000	41,000	-		-	Stock Option (Right to Buy)

Showing 1 to 50 of 185 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

32.20% Fall from 52W High

Insider Trading disclosures for Arbutus Biopharma Corp

The latest disclosure was made by David C. Hastings in Arbutus Biopharma Corp where a trade of 365,800 Stock Option (Right to Buy) done was reported to US exchanges on Feb. 14, 2025.

Screeners based on Insider Trading and SAST parameters